ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation (NCT05059444)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
- Guardant Reveal (DIAGNOSTIC_TEST)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (57 Sites)
Showing the first 25 of 57 sites.
- University of Alabama at Birmingham — Birmingham, Alabama
- Ironwood Cancer & Research Centers — Chandler, Arizona
- Genesis Cancer Center — Hot Springs, Arkansas
- University of California, San Diego — La Jolla, California
- Hoag Memorial Hospital Presbyterian — Newport Beach, California
- Redwood City — Redwood City, California
- Sutter Institute for Medical Research — Sacramento, California
- University of Colorado — Aurora, Colorado
- Memorial Healthcare System — Hollywood, Florida
- The Oncology Institute of Hope & Innovation — Lakeland, Florida
- Tulane Cancer Center — New Orleans, Louisiana
- Christus Highland/ Boniol — Shreveport, Louisiana
- Central Maine Medical Center — Lewiston, Maine
- Massachusetts General Hospital — Boston, Massachusetts
- Cancer & Hematology Centers of Western Michigan — Grand Rapids, Michigan
- Mayo Clinic (Rochester) — Rochester, Minnesota
- Astera Cancer Care — East Brunswick, New Jersey
- Icahn School of Medicine at Mount Sinai — New York, New York
- UNC- Chapel Hill — Chapel Hill, North Carolina
- The Christ Hospital Cancer Center — Cincinnati, Ohio
- Cleveland Clinic — Cleveland, Ohio
- Toledo Clinic Cancer Center — Toledo, Ohio
- Crozer-Keystone Health System — Broomall, Pennsylvania
- University of Pennsylvania — Philadelphia, Pennsylvania
- Cancer Care Associates of York — York, Pennsylvania
📞 Contact the Study Coordinator
Phone: (855) 698-8887
Email: mrdoraclestudy@guardanthealth.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Bladder Carcinoma
- Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery — Duarte, California
- Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers — Los Angeles, California
- Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers — Duarte, California
- Bladder Bank (a Prospective Banking Study) — Rochester, Minnesota
- The Vanguard Study: Testing a New Way to Screen for Cancer — Pleasanton, California
Explore by condition: All Bladder Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.